You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Coagulation state in patients with Crohns disease: the effect of infliximab therapy

Wang, Xiaobinga,b,*; Wang, Gea,b,*; Wang, Jinghuia,b,*; Liu, Shia,b; Zhou, Ruia,b; Chen, Lipinga,b; Wu, Tinga,b; Huang, Meifanga; Li, Jina; Song, Lua,b; Xia, Binga,b

European Journal of Gastroenterology & Hepatology:
doi: 10.1097/MEG.0000000000000133
Original Articles: Inflammatory Bowel Disease
Abstract

Background: Growing evidence has shown that coagulation processes play an important role in disease pathogenesis and/or disease progression in patients with inflammatory bowel disease. However, no study has ever focused on the possible influence of infliximab (IFX) therapy on the coagulation status in patients with Crohn’s disease (CD).

Objective: To investigate the difference in the coagulation biomarkers between the CD patients and the control participants, and evaluate the impact of IFX usage on the coagulation status of CD patients.

Patients and methods: A retrospective study that included a case–control study and a self-control study was designed. The medical records of CD patients and control participants were evaluated according to the inclusion and exclusion criteria. The results of laboratory tests including blood routine, coagulation, D-dimer, C-reactive protein, and erythrocyte sedimentation rate were retrieved to assess the coagulation state.

Results: In the case–control study, almost all the parameters showed a statistically significant difference between the CD patients and the control participants, except for activated partial thromboplastin time and thrombin time (the P value ranged from 0.000 to 0.002). Most of the values of the parameters reverted to normal over time during IFX therapy in the self-control study. Moreover, the fibrinogen concentration decreased obviously after IFX infusion (P=0.000) and the D-dimer concentration also decreased obviously by about half of the start value after IFX usage (P=0.018).

Conclusion: IFX therapy could ameliorate the hypercoagulable state in patients with CD.

Author Information

aDepartment of Gastroenterology/Hepatology, Zhongnan Hospital of Wuhan University

bThe Hubei Clinical Center & Key Laboratory of Intestinal & Colorectal Diseases, Wuhan, People’s Republic of China

* Xiaobing Wang, Ge Wang and Jinghui Wang contributed equally to the writing of this article.

All supplementary digital content is available directly from the corresponding author.

Correspondence to Bing Xia, MD, PhD, Department of Gastroenterology/Hepatology, Zhongnan Hospital of Wuhan University, Donghu Road 169, Wuhan 430071, People’s Republic of China Tel: +86 027 67813061; fax: +86 027 67812892; e-mail: bingxia@aliyun.com

Received February 23, 2014

Accepted May 1, 2014

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins